---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-250822"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:55:52.881884+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology reports preliminary Q3 2023 cash position of $196.5M

## Summary
- Preliminary cash, cash equivalents, and investments of $196.5M as of Sep 30, 2023, subject to quarter-end close.
- Estimate is unaudited and may change upon completion of financial statement closing procedures.
- No other Q3 financial results released; full report expected later.

## SEC filing metadata
- accession: 0001193125-23-250822
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312523250822/0001193125-23-250822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312523250822/d537542d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-250822
- JSON: https://secwatch.observer/filing/0001193125-23-250822.json
- Plain text: https://secwatch.observer/filing/0001193125-23-250822.txt

## Key facts
- Earnings Releases
  ALX ONCOLOGY HOLDINGS INC reported preliminary financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: preliminary results
  source text: ALX Oncology Holdings Inc. (the “Company”), announced its preliminary estimate of cash, cash equivalents and short-term and long-term investments for the third quarter ended September 30, 2023. Based upon preliminary estimates and information available to the Company as of the date of this Form 8-K, it had approximately $196.5 million of cash, cash equivalents and short-term and long-term investments as of September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000119312523250822/0001193125-23-250822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.